Myanmar Support for Inactivated Polio Vaccine (IPV)

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Myanmar

2. Grant number: 17-MMR-25b-X / 15-MMR-08h-Y

3. Date of Decision Letter: 19 December 2016

4. Date of the Partnership Framework Agreement: 4 April 2014

5. Programme title: NVS, IPV routine

6. Vaccine type: Inactivated Polio Vaccine (IPV)

7. Requested product presentation and formulation of vaccine\(^1\): Inactivated Polio Vaccine, 5 dose(s) per vial, LIQUID

8. Programme duration\(^2\): 2015 - 2018

9. Programme Budget (indicative): (subject to the terms of the Partnership Framework Agreement)
   Please note that endorsed or approved amounts for 2018 will be communicated in due course, taking into account updated information on country requirements and following Gavi’s review and approval processes.

<table>
<thead>
<tr>
<th></th>
<th>2015-2016</th>
<th>2017</th>
<th>Total(^3)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Programme Budget (US$)</td>
<td>1,559,972</td>
<td>1,946,000</td>
<td>3,505,972</td>
</tr>
</tbody>
</table>

10. Vaccine introduction grant: US$ 723,500 disbursed in April and July 2015 to UNICEF and WHO respectively as per the Decision Letter dated 11 Feb 2015

11. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement)\(^4\)

<table>
<thead>
<tr>
<th>Type of supplies to be purchased with Gavi funds in each year</th>
<th>2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of IPV vaccines doses</td>
<td>995,300</td>
</tr>
<tr>
<td>Annual Amounts (US$)</td>
<td>1,946,000</td>
</tr>
</tbody>
</table>

12. Procurement agency: UNICEF

13. Self-procurement: Not applicable

14. Co-financing obligations: Not applicable

\(^1\) Please refer to section 18 for additional information on IPV presentation.

\(^2\) This is the entire duration of the Programme.

\(^3\) This is the total amount endorsed by Gavi for 2015 to 2017.

\(^4\) This is the amount that Gavi has approved.
Gavi’s usual co-financing requirements do not apply to IPV. However, Myanmar is encouraged to contribute to vaccine and/or supply costs for IPV.

15. **Operational support for campaigns:** Not applicable

16. **Additional reporting requirements:**

<table>
<thead>
<tr>
<th>Reports and other information</th>
<th>Due dates</th>
</tr>
</thead>
<tbody>
<tr>
<td>To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.</td>
<td>May</td>
</tr>
<tr>
<td>In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.</td>
<td>To be agreed with Secretariat</td>
</tr>
</tbody>
</table>

17. **Financial clarifications:** The country shall address any recommendations, prioritised needs or strategic actions as described in the High Level Review Panel Report (October 2016)

18. **Other conditions:**

Due to unprecedented demand for IPV and the challenges to scale up production capacities, the global IPV supply is highly constrained and is unlikely to meet all country requirements in the short term. As a consequence, the actual presentation and number of doses shipped may differ from those specified in this Decision Letter. In order to mitigate these circumstances, you are strongly encouraged to optimally manage available supply and follow recommendations and guidelines from WHO and UNICEF to reduce vaccine wastage.

Signed by,
On behalf of Gavi

Hind Khatib-Othman
Managing Director, Country Programmes
19 December 2016

[Signature]
Barry Greene
Managing Director
Finance & Operations
The GAVI Alliance

20 December 2016